Companies › Orbus Therapeutics
1 active drug program in 8 registered trials: 3 Phase 1, 3 Phase 2, 1 Phase 4, 1 Phase 3; Immunology, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eflornithine Ornithine decarboxylase inhibitor | ODC1 | Phase 1 | Glioblastoma, IDH-wildtype; Hirsuitism; Colorectal Neoplasms; Prostate Cancer … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06976424 | Eflornithine | Phase 4 | Hirsuitism | Immunology | Dec 2025 |
| NCT05879367 | Eflornithine | Phase 1 | Glioblastoma, IDH-wildtype | Oncology | Jun 2026 |
| NCT06059118 | Eflornithine | Phase 2 | Prostate Cancer | Oncology | Jan 2027 |
| NCT01349881 | Eflornithine | Phase 3 | Colorectal Neoplasms | Oncology | Sep 2027 |
| NCT03794349 | Eflornithine | Phase 2 | High Risk Neuroblastoma | Oncology | Mar 2029 |
| NCT07468136 | Eflornithine | Phase 1 | Anaplastic Oligodendroglioma | Oncology | Oct 2030 |
| NCT07321912 | Eflornithine | Phase 2 | Osteosarcoma | Oncology | Jun 2031 |
| NCT06465199 | Eflornithine | Phase 1 | Atypical Teratoid/Rhabdoid Tumor | Oncology | May 2033 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.